Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins

Nuclear Medicine and Biology

Volumn 31, Issue 8, 2004, Pages 1061-1071

  Talanov, Vladimir S ^a   Yordanov, Alexander T ^a   Garmestani, Kayhan ^a   Milenic, Diane E ^a   Arora, Hans C ^a   Plascjak, Paul S ^b   Eckelman, William C ^b   Waldmann, Thomas A ^a   Brechbiel, Martin W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Particle; 211At; Astatine; Monoclonal antibody; Radioimmunotherapy; SAPS

Indexed keywords

ACETIC ACID; ASTATINE 211; BENZOIC ACID ESTER DERIVATIVE; ESTER DERIVATIVE; IODINE 125; MONOCLONAL ANTIBODY; N CHLOROSUCCINIMIDE; OXIDIZING AGENT; PROTEIN; RADIOISOTOPE; SUCCINIC ACID DERIVATIVE; SUCCINIMIDYL 4 METHOXYMETHYL 3 ASTATOBENZOATE; SUCCINIMIDYL 4 METHYLTHIOMETHYL 3 ASTATOBENZOATE; SUCCINIMIDYL N 4 IODOPHENETHYLSUCCINAMATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; SYNTHESIS; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; CELL LINE, TUMOR; COLONIC NEOPLASMS; CROSS-LINKING REAGENTS; FEMALE; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; ORGAN SPECIFICITY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 10644244519     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.08.005     Document Type: Article

References (56)

1. T. Gura Therapeutic antibodies: magic bullets hit the target Nature 417 2002 584 586
2. 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma Curr. Pharm. Biotechnol. 2 2001 341 349
3. N. Pandit-Taskar, P.A. Hamlin, S. Reyes, S.M. Larson, and C.R. Divgi New strategies in radioimmunotherapy for lymphoma Curr. Oncol. Rep. 5 2003 364 371
4. 177Lu-CC49: a phase I/II study Gynecol. Oncol. 65 1997 94 101
5. 131I-anti-B1 (anti-CD20) antibody N. Engl. J. Med. 329 1993 459 465
6. S.J. Knox, M.L. Goris, K. Trisler, R. Negrim, T. Davis, and T.-M. Liles Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin. Cancer Res. 2 1996 457 470
7. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas Lancet 346 1995 336 340
8. T.M. Waldmann, J.D. White, J.A. Carrasquillo, J.C. Reynolds, C.H. Paik, and O.A. Gansow Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac Blood 86 1995 4063 4075
9. J.G. Jurcic, P.C. Caron, and D.A. Scheinberg Monoclonal antibody therapy of leukemia and lymphoma J.T. August M.W. Anders F. Murad J.T. Coyle Advances in pharmacology vol. 33 1995 Academic Press New York 287 314
10. J.A. O'Donoghue, M. Bardies, and T.E. Wheldon Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides J. Nucl. Med. 36 1995 1902 1909
11. 90Y-DOTA-biotin Cancer Res. 62 2002 5755 5760
12. M. Zhang, Z. Yao, K. Garmestani, D. Axworthy, Z. Zhang, and B. Mallett Pretargeting radioimmunotherapy of a murine model of adult T cell leukemia (ATL) with the alpha emitting radionuclide, Bi-213 Blood 100 2002 208 216
13. M. Zhang, Z. Zhang, K. Garmestani, J. Schultz, D.B. Axworthy, and C.K. Goldman Pretarget radioimmunotherapy provides effective treatment for lymphoma and leukemia xenografts Proc. Natl. Acad. Sci. U. S. A. 100 2003 1891 1895
14. E. Dadachova, A. Nakouzi, R.A. Bryan, and A. Casadevall Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection Proc. Natl. Acad. Sci. U. S. A. 100 2003 10942 10947
15. 223Ra demonstrated in an experimental skeletal metastases model Cancer Res. 62 2002 3120 3125
16. M. Miederer, C. Seidl, G. Beyer, E. David, D.E. Charlton, and S. Vranjes-Duric Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein Radiat. Res. 159 2003 612 620
17. K.A. Hamacher, and G. Sgouros Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters Med. Phys. 28 2001 1857 1874
18. J.L. Humm, and L.M. Cobb Nonuniformity of tumor dose in radioimmunotherapy J. Nucl. Med. 31 1990 75 83
19. M.R. McDevitt, G. Sgouros, R.D. Finn, J.L. Humm, J.G. Jurcic, and S.M. Larson Radioimmunotherapy with alpha-emitting nuclides Eur. J. Nucl. Med. 25 1998 1341 1351
20. M.R. Zalutsky, and G. Vaidyanathan Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy Curr. Pharm. Des. 6 2000 1433 1455
21. C. Aaij, W.R.J.M. Tschroots, L. Lindner, and T.E.W. Feltkamp The preparation of astatine labelled proteins Int. J. Appl. Radiat. Isot. 26 1975 25 30
22. A.T.M. Vaughan, and J.H. Fremlin The preparation of astatine labelled proteins using an electrophilic reaction Int. J. Nucl. Med. Biol. 5 1978 229 230
23. 2 fragment Cancer Res. 50 1990 3514 3520
24. P.K. Garg, S. Garg, and M.R. Zalutsky N-Succinimidyl 4-methyl-3-(tri-n- butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies Nucl. Med. Biol. 20 1993 379 387
25. 211At-IgG conjugate which is stable in vivo Int. J. Appl. Radiat. Isot. 35 1984 1005 1008
26. 211At labeling of humanized Anti-Tac Nucl. Med. Biol. 28 2001 845 856
27. 2 fragments with the α-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity Proc. Natl. Acad. Sci. U. S. A. 86 1989 7149 7153
28. M.R. Zalutsky, M.G. Stabin, R.H. Larsen, and D.D. Bigner Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate Nucl. Med. Biol. 24 1997 255 261
29. 211At produced in disposable internal and external bismuth targets Nucl. Med. Biol. 25 1998 89 93
30. Y.V. Norseev Gas-chromatographic characterization of physicochemical properties of astatine compounds Radiochemistry 37 1995 224 232
31. - mit Thioharnstoff und Thioharnstoffderivaten Z. Chem. 23 1983 346 347
32. R. Dreyer, I. Dreyer, S. Fischer, H. Hartmenn, and F. Rosch Synthesis and characterization of cationic astatine compounds with sulfur-containing ligands stable in aqueous solutions J. Radioanal. Nucl. Chem. Lett. 96 1985 333 342
33. 211At and its preliminary animal experiment J. Nucl. Radiochem. Sci. 14 1992 159 165
34. R. Ludwig, R. Dreyer, and S. Fischer First investigations of complex formation of At (III) with phosphorus organic compounds Radiochim. Acta 47 1989 129 130
35. R. Ludwig, and S. Fischer Zur At (I)-Komplexbildung mit Triphenylphosphin und Triphenylphosphinselenid ZfI-Mitt. 165 1991 92 93 [CA 116:222441x]
36. R. Ludwig, S. Fischer, R. Dreyer, R. Jacobi, and J. Beger Complex formation equilibria between astatine (I) and sulfur-containing chelating ligands Polyhedron 10 1991 11 17
37. R. Ludwig, S. Fischer, R. Dreyer, R. Jacobi, and J. Beger Zu Komplexbildungsgleichgewichten zwischen At (I) und schwefelhaltigen Poldanden ZfI-Mitt. 165 1992 94 95 [CA 116:222442y]
38. G.W.M. Visser, and E.L. Diemer Inorganic astatine chemistry: formation of complexes of astatine Radiochim. Acta 33 1983 145 151
39. G.W.M. Visser Inorganic astatine chemistry. Part II: the chameleon behavior and electrophilicity of At-species Radiochim. Acta 47 1989 97 103
40. 211At-calix [4] arene complex J. Label. Compd. Radiopharm. 43 2000 1219 1225
41. I.G. Stara, I. Stary, A. Kollarovic, F. Teply, D. Saman, and P. Fiedler Coupling reactions of ortho-substituted halobenzenes with alkynes. The synthesis of phenylacetylenes and symmetrical or unsymmetrical 1,2-diphenylacetylenes Collect. Czechoslov. Chem. Commun. 64 1999 649 672
42. D.R. Coulson, L.C. Satek, and S.O. Grim Tetrakis(triphenylphosphine) palladium (0) Inorg. Synth. XIII 1972 121 124
43. D. Colcher, A.M. Keenan, S.M. Larson, and J. Schlom Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts Cancer Res. 44 1984 5744 5781
44. 177Lu for radioimmunotherapeutic applications Nucl. Med. Biol. 29 2002 431 442
45. R.H. Tom, L.H. Rutzky, and M.H. Jakstys Human colonic adenocarcinoma cells. Establishment and description of a new cell line In Vitro 12 1976 180 191
46. M. Kosugi, S. Konju, A. Ohtani, and T. Migita Palladium-catalyzed reaction of aryl bromides with bis (tributyltin) Chem. Lett. 1981 82 90
47. 111In labeled Herceptin Nucl. Med. Biol. 29 2002 599 606
48. 211At]astato-3-pyridinecarboxylate Nucl. Med. Biol. 26 1999 405 411
49. Z. Yao, K. Garmestani, K.J. Wong, L. Park, E. Dadachova, and A. Yordanov Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody J. Nucl. Med. 42 2001 1538 1544
50. R.G. Pearson Hard and soft acids and bases J. Am. Chem. Soc. 85 1963 3533 3539
51. S. Milesz, Y.V. Norseev, Z. Szücs, and L. Vasáros Characterization of DTPA complexes and conjugated antibodies of astatine J. Radioanal. Nucl. Chem. Lett. 137 1989 365 372
52. D.S. Wilbur, M.D. Hylarides, and A.R. Fritzberg Reactions of organometallic compounds with astatine-211. Application to protein labeling Radiochim. Acta 47 1989 137 142
53. D.S. Wilbur Potential use of alpha emitting radionuclides in the treatment of cancer Antib. Immunoconjug., Radiopharm. 4 1991 85 97
54. S. Lindegren, T. Bäck, and H.J. Jensen Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields Appl. Radiat. Isot. 55 2001 157 160
55. 211At Appl. Radiat. Isot. 54 2001 839 844
56. A. Sjöström, V. Tolmachev, O. Lebeda, J. Koziorowski, J. Carlsson, and H. Lundqvist Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group J. Radioanal. Nucl. Chem. 256 2003 191 197